Cargando…

The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada

BACKGROUND: Cross‐sectional data on patient burden in adults with atopic dermatitis (AD) from real‐world clinical practice are limited. OBJECTIVE: This study compared patient‐reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe. METHODS: This s...

Descripción completa

Detalles Bibliográficos
Autores principales: de Bruin‐Weller, M., Gadkari, A., Auziere, S., Simpson, E.L., Puig, L., Barbarot, S., Girolomoni, G., Papp, K., Pink, A.E., Saba, G., Werfel, T., Eckert, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318704/
https://www.ncbi.nlm.nih.gov/pubmed/31587373
http://dx.doi.org/10.1111/jdv.16003
_version_ 1783550914253029376
author de Bruin‐Weller, M.
Gadkari, A.
Auziere, S.
Simpson, E.L.
Puig, L.
Barbarot, S.
Girolomoni, G.
Papp, K.
Pink, A.E.
Saba, G.
Werfel, T.
Eckert, L.
author_facet de Bruin‐Weller, M.
Gadkari, A.
Auziere, S.
Simpson, E.L.
Puig, L.
Barbarot, S.
Girolomoni, G.
Papp, K.
Pink, A.E.
Saba, G.
Werfel, T.
Eckert, L.
author_sort de Bruin‐Weller, M.
collection PubMed
description BACKGROUND: Cross‐sectional data on patient burden in adults with atopic dermatitis (AD) from real‐world clinical practice are limited. OBJECTIVE: This study compared patient‐reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe. METHODS: This study included adults (18–65 years) diagnosed with AD by dermatologists, general practitioners or allergists. Participants categorized as mild (n = 547; 37.3%), moderate (n = 520; 35.4%) or severe (n = 400; 27.3%) based on Investigator's Global Assessment completed a questionnaire that included pruritus and pain numerical rating scales, Patient‐Oriented‐Scoring of Atopic Dermatitis (PO‐SCORAD) itch and sleep visual analogue scales, Dermatology Life Quality Index (DLQI), and the Hospital Anxiety and Depression Scale (HADS). Participants were also stratified by inadequate efficacy/intolerance/contraindication to cyclosporine [Cyclo; n = 62 (4 mild, 18 moderate, 40 severe)] and any systemic immunomodulatory agent [IMM; n = 104 (13 mild, 31 moderate, 60 severe)] and compared with the severe group excluding participants identified as Cyclo/IMM. RESULTS: Age was similar across severity groups; the proportion of women was higher in the mild group relative to severe (61.2% vs. 50.5%; P < 0.001). Compared with moderate and mild, participants with severe AD had more comorbidities, higher itch and pain severity, worse sleep and higher levels of anxiety and depression (all P < 0.001). Mean ± SD DLQI score among participants with severe AD (16.2 ± 6.9) showed a large effect on quality of life that was higher than those with moderate (10.2 ± 6.3) and mild (5.5 ± 4.9) (both P < 0.001). The burden among Cyclo and IMM subgroups was generally similar to that of participants with severe AD. CONCLUSIONS: Adults with AD reported a substantial burden across multiple domains that was significantly higher in those with severe disease. The burden among participants in the Cyclo/IMM subgroups was similar to those with severe AD.
format Online
Article
Text
id pubmed-7318704
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73187042020-06-29 The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada de Bruin‐Weller, M. Gadkari, A. Auziere, S. Simpson, E.L. Puig, L. Barbarot, S. Girolomoni, G. Papp, K. Pink, A.E. Saba, G. Werfel, T. Eckert, L. J Eur Acad Dermatol Venereol Allergy and Eczema BACKGROUND: Cross‐sectional data on patient burden in adults with atopic dermatitis (AD) from real‐world clinical practice are limited. OBJECTIVE: This study compared patient‐reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe. METHODS: This study included adults (18–65 years) diagnosed with AD by dermatologists, general practitioners or allergists. Participants categorized as mild (n = 547; 37.3%), moderate (n = 520; 35.4%) or severe (n = 400; 27.3%) based on Investigator's Global Assessment completed a questionnaire that included pruritus and pain numerical rating scales, Patient‐Oriented‐Scoring of Atopic Dermatitis (PO‐SCORAD) itch and sleep visual analogue scales, Dermatology Life Quality Index (DLQI), and the Hospital Anxiety and Depression Scale (HADS). Participants were also stratified by inadequate efficacy/intolerance/contraindication to cyclosporine [Cyclo; n = 62 (4 mild, 18 moderate, 40 severe)] and any systemic immunomodulatory agent [IMM; n = 104 (13 mild, 31 moderate, 60 severe)] and compared with the severe group excluding participants identified as Cyclo/IMM. RESULTS: Age was similar across severity groups; the proportion of women was higher in the mild group relative to severe (61.2% vs. 50.5%; P < 0.001). Compared with moderate and mild, participants with severe AD had more comorbidities, higher itch and pain severity, worse sleep and higher levels of anxiety and depression (all P < 0.001). Mean ± SD DLQI score among participants with severe AD (16.2 ± 6.9) showed a large effect on quality of life that was higher than those with moderate (10.2 ± 6.3) and mild (5.5 ± 4.9) (both P < 0.001). The burden among Cyclo and IMM subgroups was generally similar to that of participants with severe AD. CONCLUSIONS: Adults with AD reported a substantial burden across multiple domains that was significantly higher in those with severe disease. The burden among participants in the Cyclo/IMM subgroups was similar to those with severe AD. John Wiley and Sons Inc. 2020-01-14 2020-05 /pmc/articles/PMC7318704/ /pubmed/31587373 http://dx.doi.org/10.1111/jdv.16003 Text en © 2019 Sanofi. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Allergy and Eczema
de Bruin‐Weller, M.
Gadkari, A.
Auziere, S.
Simpson, E.L.
Puig, L.
Barbarot, S.
Girolomoni, G.
Papp, K.
Pink, A.E.
Saba, G.
Werfel, T.
Eckert, L.
The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
title The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
title_full The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
title_fullStr The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
title_full_unstemmed The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
title_short The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
title_sort patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in europe and canada
topic Allergy and Eczema
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318704/
https://www.ncbi.nlm.nih.gov/pubmed/31587373
http://dx.doi.org/10.1111/jdv.16003
work_keys_str_mv AT debruinwellerm thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT gadkaria thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT auzieres thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT simpsonel thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT puigl thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT barbarots thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT girolomonig thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT pappk thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT pinkae thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT sabag thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT werfelt thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT eckertl thepatientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT debruinwellerm patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT gadkaria patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT auzieres patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT simpsonel patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT puigl patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT barbarots patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT girolomonig patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT pappk patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT pinkae patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT sabag patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT werfelt patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada
AT eckertl patientreporteddiseaseburdeninadultswithatopicdermatitisacrosssectionalstudyineuropeandcanada